University of Oslo

Founded in 1811, The University of Oslo (UiO) is Norway’s oldest and highest ranked public institution of research and higher education, with 28000 students, 7000 employees and 2700 PhD candidates. UiO has a special national responsibility for basic research and researcher training, and for managing research libraries and museums with scientific collections and public exhibitions. UiO has eight faculties, two major museums and Norway’s largest academic library. Furthermore, UiO hosts several units and research centres, and is currently coordinating nine Norwegian Centres of Excellence.

Website

Role within NuCapCure

UiO is the coordinator of NuCapCure. Apart from the project core management, the role of UiO is to carry out the in vitro proton experiments in the project and deconvolute the contribution of each treatment modality to the overall end effect. In this sense UiO will provide the initial proof of principle for NuCapCure in cell cultures. The work will be performed at the Oslo Cyclotron Laboratory using an experimental cyclotron capable of delivering up to ~20 MeV protons. In order to achieve this, proton dosimetry and Bragg peak topography are required, as well as specialized cell culture techniques. This work, apart from providing proof of principle for NuCapCure, it will also form the basis for the in-vivo proton experiments at UGMC. In addition, UiO will also manage the IP derived from the project, assist with the project communications, and preside over the project governance structures. If NuCapCure proves successful both in vitro and in vivo, UiO will lead the project translation into the clinic and the market.

Main contact(s)

Theodossis A. Theodossiou

Project coordinator

Our perspective on NuCapCure

We conceived NuCapCure as a disruptive technology aiming not only to force the cells perform the challenging chemistry, but also, when that is achieved, to specifically cure glioblastoma multiforme.

Theodossis A. Theodossiou, project coordinator

University of Oslo